Dongxing Medical Co., Ltd.

Verification opinion from Huatai United Securities Co., Ltd. regarding the change of fundraising purposes by Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Announcement from Jiangsu Dongxing Smart Medical Technology Co., Ltd. regarding the change of fundraising purposes.

Announcement of the resolutions of the 16th meeting of the 4th board of directors.

Announcement regarding the temporary postponement of the shareholders' meeting.

Independent opinion from the independent directors of the listed company regarding this major asset restructuring.

Verification opinion from Huatai United Securities Co., Ltd. that this transaction complies with Article 18 of the 'Continuing Supervision Measures for GEM Listed Companies (Trial)' and Article 8 of the 'Review Rules for Major Asset Restructuring of Listed Companies on the Shenzhen Stock Exchange.'

Verification opinion from Huatai United Securities Co., Ltd. that this transaction complies with the relevant provisions of the 'Opinions on Strengthening the Risk Prevention and Control of Integrity in Investment Banking Business by Securities Companies.'

Verification opinion from Huatai United Securities Co., Ltd. that this transaction complies with Article 11 of the 'Management Measures for Major Asset Restructuring of Listed Companies' and is not subject to Articles 43 and 44.

Verification opinion from Huatai United Securities Co., Ltd. that this transaction complies with Article 4 of the 'Regulatory Guidelines No. 9 for Listed Companies - Regulatory Requirements for Planning and Implementing Major Asset Restructuring.'

Verification opinion from Huatai United Securities Co., Ltd. regarding the purchase and sale of assets by the listed company within twelve months prior to this transaction.

Verification opinion from Huatai United Securities Co., Ltd. regarding the dilution of immediate returns from this transaction and compensation measures.

Verification opinion from Huatai United Securities Co., Ltd. that the relevant parties in this transaction do not fall under the circumstances specified in Article 12 of the 'Regulatory Guidelines No. 7 for Listed Companies - Supervision of Abnormal Trading Related to Major Asset Restructuring' and Article 30 of the 'Self-Regulatory Guidelines No. 8 for Listed Companies on the Shenzhen Stock Exchange.'

Verification opinion from Huatai United Securities Co., Ltd. regarding the industry policy and transaction type of this transaction.

Verification opinion from Huatai United Securities Co., Ltd. regarding the stock price fluctuations of Jiangsu Dongxing Smart Medical Technology Co., Ltd. before the announcement of this restructuring information.

Special verification opinion from Huatai United Securities Co., Ltd. regarding the establishment and implementation of the insider information registrant system of Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Verification opinion on the establishment and implementation of the insider information registrant system of Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Special verification opinion from Huatai United Securities Co., Ltd. regarding the occurrence of performance anomalies before the restructuring of Jiangsu Dongxing Smart Medical Technology Co., Ltd. or the existence of proposed asset disposals in this restructuring.

Special verification opinion regarding the occurrence of performance anomalies before the restructuring of Jiangsu Dongxing Smart Medical Technology Co., Ltd. or the existence of proposed asset disposals in this restructuring.

Special verification explanation from Lixin Certified Public Accountants (Special General Partnership) regarding the occurrence of performance anomalies before the restructuring of Jiangsu Dongxing Smart Medical Technology Co., Ltd. or the existence of proposed asset disposals in this restructuring.

Verification opinion from Huatai United Securities Co., Ltd. that this transaction does not constitute a restructuring listing situation as defined in Article 13 of the 'Management Measures for Major Asset Restructuring of Listed Companies.'

Commitment letter issued by Huatai United Securities Co., Ltd. based on thorough due diligence and internal review.

Commitment letter from the listed company regarding the authenticity, accuracy, and completeness of the information.

Commitment letter regarding the authenticity, accuracy, and completeness of the information (controlling shareholder, actual controller, and concerted actors of the listed company).

Commitment letter from all directors and senior executives of the listed company regarding the authenticity, accuracy, and completeness of the information.

Commitment letter from the counterparty regarding the authenticity, accuracy, and completeness of the information (Tianhui Technology).

Commitment letter from the counterparty regarding the authenticity, accuracy, and completeness of the information (Bao Shijun).

Explanation by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd. regarding the purchase and sale of assets within twelve months prior to this transaction.

Explanation by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd. regarding the stock price fluctuations of the listed company prior to the first disclosure of this transaction.

Explanation by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd. that the relevant parties in this transaction do not fall under the circumstances specified in Article 12 of the 'Regulatory Guidelines No. 7 for Listed Companies - Supervision of Abnormal Trading Related to Major Asset Restructuring' and Article 30 of the 'Self-Regulatory Guidelines No. 8 for Listed Companies on the Shenzhen Stock Exchange.'

Explanation by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd. that this transaction complies with Article 4 of the 'Regulatory Guidelines No. 9 for Listed Companies - Regulatory Requirements for Planning and Implementing Major Asset Restructuring.'

Explanation by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd. that this transaction complies with Article 11 of the 'Management Measures for Major Asset Restructuring of Listed Companies' and is not subject to Articles 43 and 44.

Explanation by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd. that this transaction complies with Article 18 of the 'Continuing Supervision Measures for GEM Listed Companies (Trial)' and Article 8 of the 'Review Rules for Major Asset Restructuring of Listed Companies on the Shenzhen Stock Exchange.'

Explanation by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd. regarding the dilution of immediate returns from this transaction and related compensation measures.

Explanation by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd. regarding the independence of the evaluation agency, the reasonableness of the evaluation assumptions, the relevance of the evaluation methods and purposes, and the fairness of the evaluation pricing.

Explanation by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd. on whether this transaction constitutes a major asset restructuring and restructuring listing.

Explanation by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd. that this transaction does not constitute a related party transaction.

Explanation of the completeness, compliance, and validity of legal documents submitted for this transaction by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Explanation of the confidentiality measures and confidentiality system adopted for this transaction by the board of directors of Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Explanation of the asset valuation of all equity interests of Wuhan Yijiaobao Biomaterials Co., Ltd. involved in the equity acquisition proposed by Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Asset Valuation Report on the Entire Equity Value of Wuhan Yijiaobao Biomaterials Co., Ltd. Involved in Jiangsu Dongxing Smart Medical Technology Co., Ltd.'s Proposed Equity Acquisition

Review Report and Pro Forma Financial Statements of Jiangsu Dongxing Smart Medical Technology Co., Ltd. for 2025

Audit Report and Financial Statements of Wuhan Yijiaobao Biomaterials Co., Ltd. for the Year 2024 to 2025

Legal Opinion on Jiangsu Dongxing Smart Medical Technology Co., Ltd.'s Cash Purchase of Assets

Independent Financial Advisor Report by Huatai United Securities Co., Ltd. on Jiangsu Dongxing Smart Medical Technology Co., Ltd.'s Major Asset Purchase

Announcement on the Disclosure of the Restructuring Report and General Risk Warning

Summary of Major Asset Purchase Report (Draft) by Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Major Asset Purchase Report (Draft) by Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Legal Opinion from Beijing Tianyuan Law Firm on Jiangsu Dongxing Smart Medical Technology Co., Ltd.'s 2025 Annual Shareholders' Meeting

Announcement of the 2025 Annual Shareholders' Meeting Resolutions

Training Situation Report for 2025 During the Continuous Supervision Period of Jiangsu Dongxing Smart Medical Technology Co., Ltd. by Huatai United Securities

Annual Tracking Report for 2025 of Jiangsu Dongxing Smart Medical Technology Co., Ltd. by Huatai United Securities

Summary Report on the First Public Offering of Stocks and Listing on the Growth Enterprise Market of Jiangsu Dongxing Smart Medical Technology Co., Ltd. by Huatai United Securities

Announcement on the progress of planning a major asset restructuring

Independent Director's 2025 Annual Work Report (Shangguan Junjie)

Independent Director's 2025 Annual Work Report (Shen Shijuan)

Independent Director's 2025 Annual Work Report (Zhu Qi)

Announcement on Holding the 2025 Online Performance Presentation

Huatai United Securities Co., Ltd. on the Verification Opinion of Jiangsu Dongxing Smart Medical Technology Co., Ltd.'s 2025 Annual Internal Control Self-Assessment Report

2025 Internal Control Audit Report of Jiangsu Dongxing Smart Medical Technology Co., Ltd.

2025 Internal Control Self-Evaluation Report

Prompt Announcement on the Disclosure of the Q1 2026 Report

Announcement on the Confirmation of Compensation (Allowances) for Directors and Senior Management for 2025 and the Compensation (Allowances) Plan for 2026

Prompt Announcement on the Disclosure of the 2025 Annual Report

2025 Board Work Report

Announcement on Changes in Accounting Policies

Announcement on the Provision for Asset Impairment in 2025

Notice of the 2025 Annual Shareholders' Meeting

Resolution Announcement of the 15th Meeting of the Fourth Board of Directors

Announcement on the Profit Distribution Plan for 2025

Q1 2026 Report

Board Special Report on the Storage, Management, and Use of Raised Funds for 2025

Huatai United Securities Co., Ltd. Special Verification Report on the Storage, Management, and Use of Raised Funds for 2025 of Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Verification Report on the Special Report on the Storage, Management, and Use of Raised Funds for 2025 of Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Verification Report on the Operating Revenue Deduction Situation Table for 2025 of Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Evaluation Report on the Performance of the Accounting Firm for 2025

Report on the Board Audit Committee's Fulfillment of Supervision Responsibilities Regarding the Accounting Firm's Performance in 2025

Special Report on Non-Operating Fund Occupation and Other Related Fund Transactions for 2025 of Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for 2025 of Jiangsu Dongxing Smart Medical Technology Co., Ltd.

Board Special Opinion on the Independence Assessment of Independent Directors

2025 Annual Audit Report

2025 Annual Report

2025 Annual Report Summary

Progress Announcement on Planning Major Asset Restructuring

Announcement on the Expiration and Implementation of the Share Reduction Plan by Shareholders Holding More Than 5% of Shares

Progress Announcement on Planning a Major Asset Restructuring